Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.36 |
| ▸ | RORC | P51449 | 6/20 | 0.35 |
| ▸ | BCL2 | P10415 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23362968 | 0.85 | BCL2 (0.43) | MAPK14NAMPTP2RY14BCL2CYP17A1 | |
| SCHEMBL30309345 | 0.83 | RORC (0.40) | MAPK14P2RY14RORCGSK3BDYRK1A | |
| SCHEMBL24868407 | 0.83 | RORC (0.40) | MAPK14P2RY14RORCGSK3BDYRK1A | |
| SCHEMBL24867846 | 0.82 | CYP17A1 (0.47) | MAPK14NAMPTP2RY14BCL2CYP17A1 | |
| SCHEMBL28998735 | 0.81 | MAPK14 (0.36) | MAPK14NAMPTRORCBCL2CYP17A1 | |
| SCHEMBL24805843 | 0.80 | MAPK14 (0.38) | MAPK14NAMPTRORCBCL2CYP17A1 | |
| SCHEMBL30309344 | 0.79 | GSK3B (0.39) | MAPK14NAMPTP2RY14RORCBCL2 | |
| SCHEMBL24867839 | 0.79 | GSK3B (0.39) | MAPK14NAMPTP2RY14RORCBCL2 | |
| SCHEMBL23363129 | 0.75 | BCL2 (0.41) | MAPK14NAMPTP2RY14BCL2CYP17A1 | |
| SCHEMBL28906211 | 0.73 | IKBKE (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2025-10-02 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| EP-4161641-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2023-04-12 | — | — | EP | disclosed |
| CN-115942972-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2023-04-07 | — | — | CN | disclosed |
| US-11584738-B2 | LPA receptor antagonists and uses thereof | GILEAD SCIENCES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584738-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | MAPK14 1474/4885NAMPT 1039/4885P2RY14 762/4885 |
| US-20230212151-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | MAPK14 1474/4885NAMPT 1039/4885P2RY14 762/4885 |
| US-20230012262-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | MAPK14 1474/4885NAMPT 1039/4885P2RY14 762/4885 |
| US-20250304554-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR4 | MAPK14 1474/4885NAMPT 1039/4885P2RY14 762/4885 |
| US-11912686-B2 | LPA receptor antagonists and uses thereof | LPAR1, LPAR2, LPAR4 | MAPK14 1474/4885NAMPT 1039/4885P2RY14 762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.